Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions

This article was originally published in The Pink Sheet Daily

Executive Summary

The medullary thyroid cancer drug's Risk Evaluation and Mitigation Strategy requires mandatory enrollment and certification of prescribers and pharmacists, which should help ensure the drug is used primarily in patients with symptomatic, progressive disease.
Advertisement

Related Content

Exelixis' Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
ApoPharma's Preemptive Safety Strategy For Ferriprox Includes Centralized Pharmacy Distribution
Forest's Celexa Adds Warning On Dose-Dependent QT Prolongation
Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges
Afinitor In Pancreatic Tumors: ODAC Sees Consistent Efficacy, But Favors Limits On Use
Pharma News, In Brief
Pharma News, In Brief
Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs
FDA Committee Backs AstraZeneca's Vandetanib For Narrower Population Of Thyroid Cancer Patients
Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS072201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel